More about the company behind the drug
Seattle Genetics is a biotechnology company that develops and promotes antibody-based therapies for cancer treatment. The company leads the industry in antibody-drug conjugate (ADC) technology which targets antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS is Seattle Genetics leading product. It’s the first in a new class of ADCs and is available in 67 countries throughout the world. ADCETRIS is approved for relapsed classical HL and relapsed sALCL. Seattle Genetics is also working to develop an ADC for metastatic urothelial cancer, in collaboration with Astellas. They have a vast pipeline of innovative therapies for blood-related cancers and solid tumors. They are committed to address unmet medical needs and improve treatment outcomes for patients. Seattle Genetics has worked with several companies on its proprietary ADC technology including: AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer.